Corrections: Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial (The Lancet Respiratory Medicine (2017) 5(7) (557–567)(S2213260017302151)(10.1016/S2213-2600(17)30215-1));Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial

The Lancet Respiratory Medicine

Volumn 5, Issue 7, 2017, Pages 557-567

  Ratjen, Felix ^a   Hug, Christopher ^b   Marigowda, Gautham ^b   Tian, Simon ^b   Huang, Xiaohong ^b   Stanojevic, Sanja ^a   Milla, Carlos E ^c   Robinson, Paul D ^d   Waltz, David ^b   Davies, Jane C ^e   Rosenfeld, Margaret ^f   Starner, Timothy ^f   Retsch Bogart, George ^f   Chmiel, James ^f   Orenstein, David ^f   Milla, Carlos ^f   Rubenstein, Ronald ^f   Walker, Seth ^f   Cornell, Alexandra ^f   Asfour, Fadi ^f   Black, Philip ^f   Colombo, John ^f   Froh, Deborah ^f   McColley, Susanna ^f   Ruiz, Fadel ^f   Quintero, Diana ^f   Casey, Alicia ^f   Mueller, Gary ^f   Flume, Patrick ^f   Livingston, Floyd ^f   Rock, Michael ^f   O'Sullivan, Brian ^f   Schmidt, Howard ^f   Lahiri, Thomas ^f   McNamara, John ^f   Chidekel, Aaron ^f   Sass, Laura ^f   Keens, Thomas ^f   Schaeffer, David ^f   Solomon, Melinda ^f   Chilvers, Mark ^f   Lands, Larry ^f   Junge, Sibylle ^f   Griese, Matthias ^f   Staab, Doris ^f   Pressler, Tacjana ^f   van Koningsburggen Rietschel, Silke ^f   Naehrlich, Lutz ^f   Reid, Alastair ^f   Balfour Lynn, Ian ^f   Urquhart, Don ^f   Lee, Timothy ^f   Munck, Anne ^f   Gaudelus, Isabelle Sermet ^f   De Boeck, Christiane ^f   Reix, Philippe ^f   Malfroot, Anne ^f   Bui, Stéphanie ^f   Selvadurai, Hiranjan ^f   Robinson, Philip ^f   Wainwright, Claire ^f   Clements, Barry ^f   Hilton, Jodi ^f   Hjelte, Lena ^f   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b VERTEX PHARMACEUTICALS   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CHLORIDE; IVACAFTOR PLUS LUMACAFTOR; PLACEBO; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CHLORIDE CHANNEL STIMULATING AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR DELTA F508; IVACAFTOR; LUMACAFTOR; QUINOLONE DERIVATIVE;

ABDOMINAL PAIN; ALLELE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUSTRALIA; BELGIUM; BODY WEIGHT; BREATHING DISORDER; CANADA; CHILD; CHLORIDE BLOOD LEVEL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DENMARK; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; F508DEL CFTR GENE; FATIGUE; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; FRANCE; GENE; GENE MUTATION; GENOTYPE; GERMANY; HEADACHE; HUMAN; LUNG CLEARANCE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MULTICENTER STUDY; NAUSEA; NOSE OBSTRUCTION; OPEN STUDY; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; SWEDEN; TREATMENT RESPONSE; UNITED KINGDOM; UNITED STATES; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CHEMISTRY; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; GENETICS; LUNG; MUCOCILIARY CLEARANCE; MUTATION; PATHOPHYSIOLOGY; QUESTIONNAIRE; SWEAT;

AMINOPHENOLS; AMINOPYRIDINES; BENZODIOXOLES; CHILD; CHLORIDE CHANNEL AGONISTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MUCOCILIARY CLEARANCE; MUTATION; QUINOLONES; SURVEYS AND QUESTIONNAIRES; SWEAT;

EID: 85020383955     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(17)30270-9     Document Type: Erratum

References (38)

1. O'Sullivan, BP, Freedman, SD, Cystic fibrosis. Lancet 373 (2009), 1891–1904.
2. Berger, HA, Anderson, MP, Gregory, RJ, et al. Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel. J Clin Invest 88 (1991), 1422–1431.
3. Choi, JY, Muallem, D, Kiselyov, K, Lee, MG, Thomas, PJ, Muallem, S, Aberrant CFTR-dependent HCO3- transport in mutations associated with cystic fibrosis. Nature 410 (2001), 94–97.
4. Derichs, N, Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Eur Respir Rev 22 (2013), 58–65.
5. Clinical and Functional Translation of CFTR (CFTR2), https://www.cftr2.org/index.php (accessed Feb 15, 2017).
6. Lukacs, GL, Mohamed, A, Kartner, N, Chang, XB, Riordan, JR, Grinstein, S, Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 13 (1994), 6076–6086.
7. Van Goor, F, Straley, KS, Cao, D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290 (2006), L1117–L1130.
8. Dalemans, W, Barbry, P, Champigny, G, et al. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354 (1991), 526–528.
9. Van Goor, F, Hadida, S, Grootenhuis, PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106 (2009), 18825–18830.
10. Van Goor, F, Hadida, S, Grootenhuis, PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 108 (2011), 18843–18848.
11. Boyle, MP, Bell, SC, Konstan, MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2 (2014), 527–538.
12. Wainwright, CE, Elborn, JS, Ramsey, BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373 (2015), 220–231.
13. Milla, CE, Ratjen, F, Marigowda, G, et al. Lumacaftor/ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR. Am J Respir Crit Care Med 195 (2017), 912–920.
14. Liou, TG, Elkin, EP, Pasta, DJ, et al. Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros 9 (2010), 250–256.
15. Tiddens, HA, Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol 34 (2002), 228–231.
16. Marshall, H, Horsley, A, Taylor, CJ, et al. Detection of early subclinical lung disease in children with cystic fibrosis by lung ventilation imaging with hyperpolarised gas MRI. Thorax, 2017, 10.1136/thoraxjnl-2016-208948 published online March 6.
17. 129Xe magnetic resonance imaging in pediatric CF subjects. Am J Respir Crit Care Med, 2017, 10.1164/rccm.201611-2228LE published online Feb 28.
18. Gustafsson, PM, De Jong, PA, Tiddens, HA, Lindblad, A, Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 63 (2008), 129–134.
19. Owens, CM, Aurora, P, Stanojevic, S, et al. Lung clearance index and HRCT are complementary markers of lung abnormalities in young children with CF. Thorax 66 (2011), 481–488.
20. O'Neill, K, Tunney, MM, Johnston, E, et al. Lung clearance index in adults and children with cystic fibrosis. Chest 150 (2016), 1323–1332.
21. Yammine, S, Singer, F, Abbas, C, Roos, M, Latzin, P, Multiple-breath washout measurements can be significantly shortened in children. Thorax 68 (2013), 586–587.
22. Jensen, R, Green, K, Gustafsson, P, et al. Standard operating procedure: multiple breath nitrogen washout, 2013, EcoMedics AG, Duernten, Switzerland.
23. Robinson, PD, Latzin, P, Verbanck, S, et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests. Eur Respir J 41 (2013), 507–522.
24. Alpern, AN, Brumback, LC, Ratjen, F, Rosenfeld, M, Davis, SD, Quittner, AL, Initial evaluation of the Parent Cystic Fibrosis Questionnaire—Revised (CFQ-R) in infants and young children. J Cyst Fibros 14 (2015), 403–411.
25. Amin, R, Subbarao, P, Jabar, A, et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 65 (2010), 379–383.
26. Amin, R, Subbarao, P, Lou, W, et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J 37 (2011), 806–812.
27. Davies, J, Sheridan, H, Bell, N, et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med 1 (2013), 630–638.
28. Kent, L, Reix, P, Innes, JA, et al. Lung clearance index: evidence for use in clinical trials in cystic fibrosis. J Cyst Fibros 13 (2014), 123–138.
29. Robinson, PD, Goldman, MD, Gustafsson, PM, Inert gas washout: theoretical background and clinical utility in respiratory disease. Respiration 78 (2009), 339–355.
30. Rowe, SM, Accurso, F, Clancy, JP, Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 4 (2007), 387–398.
31. Taylor-Cousar, J, Jain, M, Barto, TL, et al. Lumacaftor/ivacaftor (LUM/IVA) in patients (pts) with cystic fibrosis (CF) and advanced lung disease homozygous for F508del-CFTR: a 24-wk open label study. J Cyst Fibros, 2017 (in press).
32. Quittmer, AL, Modi, AC, Wainwright, C, Otto, K, Kirihara, J, Montgomery, AB, Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 135 (2009), 1610–1618.
33. Konstan, MW, McKone, EF, Moss, RB, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med 5 (2017), 107–118.
34. Stallings, VA, Stark, LJ, Robinson, KA, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 108 (2008), 832–839.
35. Borowitz, D, Baker, SS, Duffy, L, et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 145 (2004), 322–326.
36. Walkowiak, J, Nousia-Arvanitakis, S, Cade, A, et al. Fecal elastase-1 cut-off levels in the assessment of exocrine pancreatic function in cystic fibrosis. J Cyst Fibros 1 (2002), 260–264.
37. Davies, JC, Cunningham, S, Harris, WT, et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med 4 (2016), 107–115.
38. Bhardwaj, S, Canlas, K, Kahi, C, et al. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood. J Clin Gastroenterol 43 (2009), 858–864.